Summary
Cencora, Inc. (COR) has filed an 8-K to disclose the transition of certain Walgreens volume servicing outside of its prime vendor agreement. This transition, which began on July 1, 2026, was fully anticipated by the company and was factored into its previously communicated expectations for the U.S. Healthcare Solutions segment for the fourth quarter. Importantly, the prime vendor agreement itself, which represents the substantial majority of Cencora's business with Walgreens, remains unchanged. In light of this disclosed information and its prior commentary, Cencora is reaffirming its adjusted diluted Earnings Per Share (EPS) guidance range of $17.75 to $17.95 for the fiscal year 2026. This reaffirms management's confidence in the company's ability to absorb the impact of the transitioning volume and meet its full-year financial targets.
Key Highlights
- 1Disclosure of certain Walgreens volume transitioning away from Cencora, effective July 1, 2026.
- 2The transitioned volume was separate from the primary prime vendor agreement with Walgreens.
- 3The prime vendor agreement, representing the majority of Cencora's business with Walgreens, remains unchanged.
- 4The company had previously contemplated this volume shift in its August 5, 2026, fourth-quarter commentary.
- 5Cencora is reaffirming its fiscal year 2026 adjusted diluted EPS guidance range of $17.75 to $17.95.
- 6The reaffirmation of guidance suggests management confidence in absorbing the impact of the volume shift.